

---

## Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

DECEMBER 11, 2015

On December 9, 2015, [Neon Therapeutics](#), an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline.

Neon Therapeutics was represented by WilmerHale in this transaction, with Partners Richard Hoffman and [Michael Bevilacqua](#), and Associate [Ritu Gupta](#).

View Neon Therapeutics' [press release](#) for more information.